Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials

被引:17
作者
Allemann, S
Diem, P
Egger, M
Christ, ER
Stettler, C
机构
[1] Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland
[2] Univ Bern, Dept Endocrinol & Diabet, CH-3012 Bern, Switzerland
[3] Univ Bristol, MRC Hlth Serv Res Collaborat, Dept Social Med, Bristol, Avon, England
关键词
coronary heart disease; diabetes mellitus; fibrates; meta-analysis;
D O I
10.1185/030079906X89865
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the impact of lipid lowering treatment with fibrates on cardiovascular endpoints in patients with type 2 diabetes mellitus. Methods: MEDLINE (from inception to November 2005) and the Cochrane Controlled Trials Register (including Issue 3, 2005) were searched for randomised controlled trials comparing therapy with fibrates to placebo in patients with type 2 diabetes mellitus. Electronic searches were supplemented by manual searching of reference lists, reviews, conference abstracts and specialist journals. Incidence rate ratios (IRRs) were estimated using a fixed effects model. The primary endpoint was the IRR for coronary heart disease (CHD) events (a combination of non fatal myocardial infarction and death due to CHD). Secondary endpoints included: (1) death due to CHD; (2) fatal and non fatal myocardial infarction; and (3) fatal and non fatal stroke. Results: Eight trials and 12 249 patients with type 2 diabetes were included in the analyses. A total of 924 CHD events (418 and 506 in the treatment and placebo groups, respectively) occurred during a follow up of 60 395 person-years (30 106 and 30 289 in treatment and placebo groups). The combined IRR for CHD events was 0.84 (95% confidence interval [CI] 0.74-0.96, p = 0.008). The numbers needed to treat (NNTs) to prevent one CHD event over 10 years were nine and 26 for patients with and without pre-existing CHD, respectively. IRRs for death due to CHD, myocardial infarction and stroke were 0.96 ( 95% CI 0.77-1.20, p = 0.73), 0.88 (95% CI 0.69-1.12, p = 0.30) and 0.87 (95% CI 0.73-1.05, p = 0.14), respectively. Larger benefits were found when restricting the analysis to trials that were not confounded by unequal provision of additional lipid-lowering therapy. Conclusions: Fibrates are associated with a substantial reduction of CHD events, but their exact role in lipid lowering treatment of patients with type 2 diabetes mellitus remains to be defined.
引用
收藏
页码:617 / 623
页数:7
相关论文
共 33 条
[1]   CONTROLLED TRIAL OF CLOFIBRATE IN CEREBRAL VASCULAR-DISEASE [J].
ACHESON, J ;
HUTCHINSON, EC .
ATHEROSCLEROSIS, 1972, 15 (02) :177-+
[2]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[3]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[4]   Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management [J].
Beckman, JA ;
Creager, MA ;
Libby, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (19) :2570-2581
[5]  
BRANCHI A, 1993, THROMB HAEMOSTASIS, V70, P241
[6]  
Cullen J F, 1974, Trans Ophthalmol Soc U K, V94, P554
[7]   Role of fibric acid derivatives in the management of risk factors for coronary heart disease [J].
Després, JP ;
Lemieux, I ;
Robins, SJ .
DRUGS, 2004, 64 (19) :2177-2198
[8]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[9]   Effects of fibrates on serum metabolic parameters [J].
Elisaf, M .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (05) :269-276
[10]   Cardiovascular outcomes in type 2 diabetes - A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study [J].
Elkeles, RS ;
Diamond, JR ;
Poulter, C ;
Dhanjil, S ;
Nicolaides, AN ;
Mahmood, S ;
Richmond, W ;
Mather, H ;
Sharp, P ;
Feher, MD .
DIABETES CARE, 1998, 21 (04) :641-648